Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides

Chemical Research in Toxicology

Volumn 18, Issue 2, 2005, Pages 174-182

  Liu, Ju ^a   Liu, Hong ^a   Van Breemen, Richard B ^a   Thatcher, Gregory R J ^a   Bolton, Judy L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ACOLBIFENE; ACOLBIFENE QUINONE METHIDE; ADENINE; ANTINEOPLASTIC AGENT; ARZOXIFENE; DEOXYADENOSINE DERIVATIVE; DEOXYNUCLEOSIDE; DIQUINONE METHIDE; DNA; DRUG METABOLITE; GLUTATHIONE; METHYL GROUP; MONOPHENOL MONOOXYGENASE; NORARZOXIFENE; NUCLEOSIDE; PHENOL; PRODRUG; QUINONE DERIVATIVE; QUINONE METHIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN S30; CHEMICAL REACTION; CONJUGATE; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DRUG ACTIVATION; DRUG OXIDATION; DRUG STRUCTURE; ENDOMETRIUM CANCER; HALF LIFE TIME; HUMAN; HUMAN TISSUE; LIVER MICROSOME; NONHUMAN; PH; RAT; TEMPERATURE; TOXICOKINETICS;

ANIMALS; BIOTRANSFORMATION; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; FEMALE; GLUTATHIONE; HUMANS; INDOLEQUINONES; KINETICS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OLIGODEOXYRIBONUCLEOTIDES; OXIDATION-REDUCTION; PIPERIDINES; RATS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 13844264457     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx0497752     Document Type: Article

References (45)

1. Worley, R. J. (1981) Age, estrogen, and bone density. Clin. Obstet. Gynecol. 24, 203-218.
2. Stampfer, M. J., Colditz, G. A., and Willett, W. C. (1990) Menopause and heart disease. A review. Ann. N. Y. Acad. Sci. 592, 193-203; discussion 257-162.
3. Barrett-Connor, E., and Grady, D. (1998) Hormone replacement therapy, heart disease, and other considerations. Annu. Rev. Public Health 19, 55-72.
4. Meegan, M. J., and Lloyd, D. G. (2003) Advances in the science of estrogen receptor modulation. Curr. Med. Chem. 10, 181-210.
5. Jordan, V. C. (2003) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J. Med. Chem. 46, 1081-1111.
6. Furr, B. J., and Jordan, V. C. (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25, 127-205.
7. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388.
8. King, C. M. (1995) Tamoxifen and the induction of cancer. Carcinogenesis 16, 1449-1454.
9. Phillips, D. H. (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis 22, 839-849.
10. van Leeuwen, F. E., Benraadt, J., Coebergh, J. W., Kiemeney, L. A., Gimbraere, C. H., Otter, R., Schouten, L. J., Damhuis, R. A., Bontenbal, M., Diepenhorst, F. W., et al. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343, 448-452.
11. Umemoto, A., Komaki, K., Monden, Y., Suwa, M., Kanno, Y., Kitagawa, M., Suzuki, M., Lin, C. X., Ueyama, Y., Momen, M. A., Ravindernath, A., and Shibutani, S. (2001) Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice. Chem. Res. Toxicol. 14, 1006-1013.
12. Zhang, F., Fan, P. W., Liu, X., Shen, L., van Breeman, R. B., and Bolton, J. L. (2000) Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxvtamoxifen-o-quinone. Chem. Res. Toxicol. 13, 53-62.
13. Fan, P. W., Zhang, F., and Bolton, J. L. (2000) 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem. Res. Toxicol. 13, 45-52.
14. Bolton, J. L. (2002) Quinoids, quinoid radicals, and phenoxyl radicals formed from estrogens and antiestrogens. Toxicology 177, 55-65.
15. Bolton, J. L., Pisha, E., Zhang, F., and Qiu, S. (1998) Role of quinoids in estrogen carcinogenesis. Chem. Res. Toxicol. 11, 1113-1127.
16. Kim, S. Y., Suzuki, N., Laxmi, Y. R., and Shibutani, S. (2004) Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab. Rev. 36, 199-218.
17. Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A. C., Shah, A. S., Huster, W. J., Draper, M., and Christiansen, C. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641-1647.
18. Conzen, S. D. (2003) Current status of selective estrogen receptor modulators (SERMs). Cancer J. 9, 4-14.
19. Sato, M., Turner, C. H., Wang, T., Adrian, M. D., Rowley, E., and Bryant, H. U. (1998) LY353381.HCl: a novel raloxifene analogue with improved SERM potency and efficacy in vivo. J. Pharmacol. Exp. Ther. 287, 1-7.
20. Yu, L., Liu, H., Li, W., Zhang, F., Luckie, C., Van Breemen, R. B., Thatcher, G. R., and Bolton, J. L. (2004) Oxidation of Raloxifene to Quinoids: Potential Toxic Pathways via a Diquinone Methide and o-Quinones. Chem. Res. Toxicol. 17, 879-888.
21. Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15, 907-914.
22. Liu, H., Yu, L., Liu, J., van Breeman, R. B., Thatcher, G. R. J., and Bolton, J. L. (2004) Bioactivaton of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4′-fluoro substitution prevents quinoid formation. Chem. Res. Toxicol. 2005, 18, 162-173.
23. Gauthier, S., Caron, B., Cloutier, J., Dory, Y. L., Favre, A., Larouche, D., Mailhot, J., Quellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mâerand, Y., Bâelanger, A., Labrie, C., and Labrie, F. (1997) (S)-(+)-4-[7-(2,2-Dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) -ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. J. Med. Chem. 40, 2117-2122.
24. Simard, J., Labrie, C., Bâelanger, A., Gauthier, S., Singh, S. M., Mâerand, Y., and Labrie, F. (1997) Characterization of the effects of the novel nonsteroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer 73, 104-112.
25. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S. M., Merand, Y., Belanger, A., Labrie, C., and Labrie, F. (1997) Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res. 57, 3494-3497.
26. Couillard, S., Gutman, M., Labrie, C., Bâelanger, A., Candas, B., and Labrie, F. (1998) Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res. 58, 60-64.
27. Luo, S., Labrie, C., Bâelanger, A., and Labrie, F. (1997) Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz[a] anthracene-induced mammary carcinoma in the rat. Endocrinology 138, 3387-3394.
28. NIH Guidelines for the Laboratory Use of Chemical Carcinogens (1981), NIH Publication, U.S. Government Printing Office, Washington, DC, pp 81-2385.
29. Draper, R. W., Iyer, R. V., Lu, Y., and Vater, E. J. Enantioselective synthesis, U.S. Patent 6,262,270 B1, 2001.
30. Iverson, S. L., Shen, L., Anlar, N., and Bolton, J. L. (1996) Bioactivation of estrone and its catechol metabolites to quinoid-glutathione conjugates in rat liver microsomes. Chem. Res. Toxicol. 9, 492-499.
31. Freshney, R. (1987) Culture of Animal cells: A Manual of Basic Techniques, p 117, Alan R. Liss Inc., New York.
32. Filar, L. J., and Winstein, S. (1960) Preparation and behavior of simple quinone methides. Tetrahedron Lett. 25, 9-16.
33. Bolton, J. L., Comeau, E., and Vukomanovic, V. (1995) The influence of 4-alkyl substituents on the formation and reactivity of 2-methoxy-quinone methides: evidence that extended pi-conjugation dramatically stabilizes the quinone methide formed from eugenol. Chem.-Biol. Interact. 95, 279-290.
34. Kassahun, K., Davis, M., Hu, P., Martin, B., and Baillie, T. (1997) Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: identification of phase I metabolites and glutathione conjugates. Chem. Res. Toxicol. 10, 1228-1233.
35. Ramanathan, R., Cao, K., Cavalieri, E., and Gross, M. L. (1998) Mass spectrometric methods for distinguishing structural isomers of glutathione conjugates of estrone and estradiol. J. Am. Soc. Mass Spectrom. 9, 612-619.
36. Cao, K., Stack, D. E., Ramanathan, R., Gross, M. L., Rogan, E. G., and Cavalieri, E. L. (1998) Synthesis and structure elucidation of estrogen quinones conjugated with cysteine, N-acetylcysteine, and glutathione. Chem. Res. Toxicol. 11, 909-916.
37. Koop, D. R., Laethem, C. L., and Schnier, G. G. (1989) Identification of ethanol-inducible P450 isozyme 3a (P450IIE1) as a benzene and phenol hydroxylase. Toxicol. Appl. Pharmacol. 98, 278-288.
38. Olive, P. L., Banâath, J. P., and Durand, R. E. (1990) Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat. Res. 122, 86-94.
39. Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., and Monks, T. J. (2000) Role of quinones in toxicology. Chem. Res. Toxicol. 13, 135-160.
40. Thompson, D. C., Perera, K., Krol, E. S., and Bolton, J. L. (1995) o-Methoxy-4-alkylphenols that form quinone methides of intermediate reactivity are the most toxic in rat liver slices. Chem. Res. Toxicol. 8, 323-327.
41. Richard, J. P., Ameyes, T. L., Bei, L., and Stubblefield, V. (1990) The effect of β-fluorine substituents on the rate and equilibrium constants for the reactions of α-substituted 4-methoxybenzyl carbocations and on the reactivity of a simple quinone methide. J. Am. Chem. Soc. 112, 9513-9519.
42. Hulbert, P. B., and Grover, P. L. (1983) Chemical rearrangement of phenol-epoxide metabolites of polycyclic aromatic hydrocarbons to quinone-methides. Biochem. Biophys. Res. Commun. 117, 129-134.
43. Bolton, J. L., Acay, N. M., and Vukomanovic, V. (1994) Evidence that 4-allyl-o-quinones spontaneously rearrange to their more electrophilic quinone methides: potential bioactivation mechanism for the hepatocarcinogen safrole. Chem. Res. Toxicol. 7, 443-450.
44. Thompson, D., Constantin-Teodosiu, D., Norbeck, K., Svensson, B., and Moldâeus, P. (1989) Metabolic activation of eugenol by myeloperoxidase and polymorphonuclear leukocytes. Chem. Res. Toxicol. 2, 186-192.
45. Yao, D., Zhang, F., Yu, L., Yang, Y., van Breemen, R. B., and Bolton, J. L. (2001) Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones. Chem. Res. Toxicol. 14, 1643-1653.